Exagen Inc. (XGN)

US — Healthcare Sector

Peers: SERA FONR STIM TELA PHAT IGMS KRRO

Automate Your Wheel Strategy on XGN

With Tiblio's Option Bot, you can configure your own wheel strategy including XGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol XGN
Rev/Share 2.7916
Book/Share 0.9975
PB 8.4207
Debt/Equity 0.1376
CurrentRatio 4.9525
ROIC -0.2788

MktCap 184830240.0
FreeCF/Share -0.758
PFCF -11.5635
PE -10.4311
Debt/Assets 0.0493
DivYield 0
ROE -1.3626

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Upgrade	XGN	KeyBanc Capital Markets	Sector Weight	Overweight	--	$12	July 30, 2025
Initiation	XGN	Craig Hallum	--	Buy	--	$12	July 23, 2025

News

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

XGN
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral

Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Margarate Elizabeth Boeye - William Blair & Company L.L.C.

image for news Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

XGN
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

image for news Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?

XGN
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

image for news Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

XGN
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer.

image for news Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

Exagen Inc. Prices Public Offering of Common Stock

XGN
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.

image for news Exagen Inc. Prices Public Offering of Common Stock

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

XGN
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

image for news Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

XGN
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen the balance sheet.

image for news Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

About Exagen Inc. (XGN)

IPO Date 2019-09-19
Website https://www.exagen.com
Industry Medical - Diagnostics & Research
CEO John Aballi
Employees 209

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.